Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

BACKGROUND: The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also cause genitourinary infections, polyuria, or volu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Hiroki, Okada, Sadanori, Mohri, Takako, Kanda, Eiichiro, Inaba, Naoyuki, Hirasawa, Yoko, Seino, Hiroaki, Kuroda, Hisamoto, Hiyoshi, Toru, Niiya, Tetsuji, Ishii, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831584/
https://www.ncbi.nlm.nih.gov/pubmed/29507611
http://dx.doi.org/10.1186/s13098-018-0313-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831584/
https://www.ncbi.nlm.nih.gov/pubmed/29507611
http://dx.doi.org/10.1186/s13098-018-0313-x

Ejemplares similares